MCID: IND003
MIFTS: 24

Indolent Myeloma

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Indolent Myeloma

MalaCards integrated aliases for Indolent Myeloma:

Name: Indolent Myeloma 12 15 73
Indolent Multiple Myeloma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9550

Summaries for Indolent Myeloma

MalaCards based summary : Indolent Myeloma, also known as indolent multiple myeloma, is related to extramedullary plasmacytoma and waldenstroem's macroglobulinemia, and has symptoms including bone pain An important gene associated with Indolent Myeloma is MYOM2 (Myomesin 2). The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and brain.

Related Diseases for Indolent Myeloma

Graphical network of the top 20 diseases related to Indolent Myeloma:



Diseases related to Indolent Myeloma

Symptoms & Phenotypes for Indolent Myeloma

UMLS symptoms related to Indolent Myeloma:


bone pain

Drugs & Therapeutics for Indolent Myeloma

Drugs for Indolent Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2,Phase 1 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
3
Lactulose Approved Phase 2 4618-18-2 11333
4
Zoledronic acid Approved Phase 2 118072-93-8 68740
5
Bismuth Subsalicylate Approved, Vet_approved Phase 2 14882-18-9 53629521
6
Magnesium oxide Approved Phase 2 1309-48-4 14792
7
Pamidronate Approved Phase 2 40391-99-9 4674
8
Magnesium hydroxide Approved, Investigational Phase 2 1309-42-8
9
Bisacodyl Approved Phase 2 603-50-9
10
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
11 Autonomic Agents Phase 2,Phase 1
12 Hormones Phase 2,Phase 1
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
14 Antineoplastic Agents, Hormonal Phase 2,Phase 1
15 Anti-Inflammatory Agents Phase 2,Phase 1
16 Antiemetics Phase 2,Phase 1
17 HIV Protease Inhibitors Phase 2,Phase 1
18
protease inhibitors Phase 2,Phase 1
19 Hormone Antagonists Phase 2,Phase 1
20 glucocorticoids Phase 2,Phase 1
21 Gastrointestinal Agents Phase 2,Phase 1
22 Antirheumatic Agents Phase 2,Phase 1
23 Interleukin 1 Receptor Antagonist Protein Phase 2,Phase 1
24 BB 1101 Phase 2,Phase 1
25 Peripheral Nervous System Agents Phase 2,Phase 1
26 Angiogenesis Modulating Agents Phase 2,Phase 1
27 Immunosuppressive Agents Phase 2,Phase 1
28 Immunologic Factors Phase 2,Phase 1
29 Bone Density Conservation Agents Phase 2
30 Diphosphonates Phase 2
31 Anti-Infective Agents Phase 2,Phase 1
32 Anti-Bacterial Agents Phase 2,Phase 1
33 Angiogenesis Inhibitors Phase 2,Phase 1
34 Siltuximab Approved, Investigational Phase 1 541502-14-1
35 Antibodies Phase 1
36 Antibodies, Monoclonal Phase 1
37 Immunoglobulins Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma Completed NCT00635154 Phase 2 Dexamethasone acetate
2 Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide Completed NCT00083382 Phase 2 Pamidronate;Thalidomide;Zometa
3 Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma Suspended NCT02492750 Phase 1, Phase 2 Dexamethasone;Lenalidomide
4 A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Completed NCT01219010 Phase 1
5 Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging Unknown status NCT01780766
6 Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM. Active, not recruiting NCT01079429

Search NIH Clinical Center for Indolent Myeloma

Genetic Tests for Indolent Myeloma

Anatomical Context for Indolent Myeloma

MalaCards organs/tissues related to Indolent Myeloma:

41
Bone, Bone Marrow, Brain, B Cells

Publications for Indolent Myeloma

Articles related to Indolent Myeloma:

# Title Authors Year
1
Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents. ( 29118703 )
2017
2
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. ( 20730790 )
2010
3
Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. ( 19181642 )
2009
4
A smoldering/indolent myeloma with extensive abdominal presentation--case report. ( 16986300 )
2006
5
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. ( 12100153 )
2002
6
Smoldering, asymptomatic stage 1, and indolent myeloma. ( 12057049 )
2000
7
Coexistence of Polycythaemia Vera with Indolent Myeloma in the same Patient. ( 27406804 )
1997
8
Localized and indolent myeloma. ( 7407416 )
1980

Variations for Indolent Myeloma

Expression for Indolent Myeloma

Search GEO for disease gene expression data for Indolent Myeloma.

Pathways for Indolent Myeloma

GO Terms for Indolent Myeloma

Cellular components related to Indolent Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.62 ANXA5 B2M

Sources for Indolent Myeloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....